<DOC>
	<DOCNO>NCT00074646</DOCNO>
	<brief_summary>Phase I trial CC-8490 treatment subject recurrent/refractory high-grade glioma</brief_summary>
	<brief_title>Phase I Trial CC-8490 Treatment Subjects With Recurrent/Refractory High-Grade Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<criteria>Patients glioblastoma multiforme ( GBM ) , gliosarcoma , anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic mixed oligoastrocytoma ( AMO ) , malignant glioma/astrocytoma NOS ( otherwise specify ) . Also include radiographically diagnose infiltrate brain stem gliomas amenable biopsy . Other CNS tumor histology eligible trial . Patients must show either evidence tumor recurrence progression CT ( preferably ) MRI scan perform within 21 day prior registration biopsy proven recurrent glioma within last 12 week prior enrollment ( order allow enrollment patient recurrent gliomas undergone complete radiographic resection radiographic evaluable disease ) Patients undergone recent resection recurrent progressive tumor eligible two week surgery . Patient must fail prior radiation therapy must interval great equal 2 week completion radiation therapy study entry . All patient must sign informed consent , cognitively impaired , assigned DPA , indicate aware investigational nature study . Patients must &gt; 18 year old , must life expectancy &gt; 8 week . Patients must Karnofsky performance status &gt; 60 . Additionally , patient must least 6 week nitrosoureas , 4 week temozolomide carboplatin , 3 week procarbazine , 2 week last vincristine administration . Patients must least 4 week cytotoxic therapy list 2 week noncytotoxic agent ( e.g. , interferon , tamoxifen ) . Patients must adequate bone marrow function ( granulocyte count &gt; = 1500/mm3 , platelet count &gt; 100,000/mm3 , hemoglobin &gt; 8 gm % ) , adequate liver function ( total bilirubin &lt; = 1.5 mg/dL , AST/ALT &lt; = 2 x ULN ) , adequate renal function ( creatinine &lt; = 1.5 mg/dL creatinine clearance &gt; 60 cc/min ) start therapy . These test must perform within 14 day prior registration . Eligibility level hemoglobin may reach transfusion . Eligibility level platelet may reach transfusion . Patients must either receive steroid , stable dose steroid least five day prior registration . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) ineligible , unless complete remission therapy disease minimum 3 year . Patients must pregnant nursing , patient ( men woman ) must willing practice birth control 2 month treatment CC8490 . Women childbearing potential ( WCBP ) sexually active must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) . Patients must able swallow capsule whole . Patients , view treat physician , significant active cardiac , hepatic , renal , psychiatric disease would significantly increase risk use CC8490 ineligible . Concurrent use standard chemotherapeutics investigative agent . Pregnant lactating female . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study , obscure evaluation toxicity alters drug metabolism . Use experimental study drug within 28 day registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>CC-8490</keyword>
	<keyword>CC8490</keyword>
	<keyword>Glio</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Malignant Gliomas</keyword>
</DOC>